On April 25, 2008, Actavis Totowa LLC initiated a Class I nationwide recall of Digitek oral tablets after it was discovered that the tablets may contain twice the approved level of active ingredient than is appropriate.  Digitek is a drug that is prescribed to treat heart failure and abnormal heart rhythms. 

On March 31, 2009, Caraco Pharmaceutical Laboratories, Ltd. initiated a recall of all lots of Digoxin tablets due to the possibility that they may differ in size and therefore could have more of the active ingredient, digoxin.  This recall includes Digoxin, USP, 0.125 mg, and Digoxin, USP, 0.25 mg, distributed prior to March 31, 2009, which are not expired and are within the expiration date of September, 2011.

Ingesting double strength Digitek or Digoxin tablets pose a risk of digitalis toxicity in patients with renal failure.  Adverse events associated with an overdose can include:

• Nausea,
• Vomiting,
• Dizziness,
• Low blood pressure,
• Cardiac instability, 
• Bradycardia, and
• Death

If you, or someone you know, experienced any of the above-mentioned symptoms or injuries, contact us today for a free consultation at (800) 351-8588.  You may also  click here to leave a message and a representative from our office will contact you directly. 

Click here for the FDA's Recall Notice regarding Digitek.

Click here for the FDA's Recall Notice regarding Digoxin.

Click here for news regarding a Digitek Class Action filed by Capretz & Associates.

For more information visit our other Digitek (Digoxin) website at: www.digiteklawyer.net